|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2006-7-10
|
|
pubmed:abstractText |
Polyclonal human intravenous immunoglobulin (IVIG) has been advocated as an adjunct to therapy in severe invasive streptococcal toxic shock because of its ability to neutralize superantigen toxins. The aim of this study was to assess IVIG therapeutic efficacy in an experimental model of streptococcal toxic shock.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0305-7453
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
58
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
117-24
|
|
pubmed:dateRevised |
2007-2-20
|
|
pubmed:meshHeading |
pubmed-meshheading:16670109-Animals,
pubmed-meshheading:16670109-Disease Models, Animal,
pubmed-meshheading:16670109-HLA-DQ Antigens,
pubmed-meshheading:16670109-Humans,
pubmed-meshheading:16670109-Immunoglobulins, Intravenous,
pubmed-meshheading:16670109-Inflammation,
pubmed-meshheading:16670109-Mice,
pubmed-meshheading:16670109-Mice, Transgenic,
pubmed-meshheading:16670109-Muscle, Skeletal,
pubmed-meshheading:16670109-Shock, Septic,
pubmed-meshheading:16670109-Streptococcal Infections,
pubmed-meshheading:16670109-Streptococcus pyogenes,
pubmed-meshheading:16670109-Superantigens
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Human intravenous immunoglobulin for experimental streptococcal toxic shock: bacterial clearance and modulation of inflammation.
|
|
pubmed:affiliation |
Department of Infectious Diseases, Imperial College London, Hammersmith Hospital Du Cane Road, London W12 0NN, UK. s.sriskandan@imperial.ac.uk
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
